A Nerve Health Supplement Guide

Sorting them out saves confusion later, because a supplement aisle treats them as one subject and they are not.

A supplement aisle sells to all three at once. Only the lower two rows have research behind them.

The consequence for anyone standing in front of a shelf: if your problem is mechanical, the ingredients below are addressed to a different question.

It also explains a pattern that looks strange at first. Almost every trial quoted on a nerve label was run in people with diabetes, because that is the population large enough to study. Whether the findings transfer to somebody without diabetes is an open question, and an honest label does not pretend otherwise.

Alpha lipoic acid is a compound the body makes in small amounts and uses in mitochondrial energy production. It is also an antioxidant working in both water and fat, which is where the research interest began.

The oral trial programme is coherent for once. ALADIN III ran for seven months, SYDNEY 2 compared 600, 1,200 and 1,800 mg a day over five weeks, and NATHAN 1 followed people for four years. The dose that survived is 600 mg once daily: SYDNEY 2 found the higher arms brought more nausea without more benefit, which is why 600 mg is the number on serious labels.

What it achieved is worth stating precisely. A 2023 meta-analysis found improvement in symptom scores, and a 2026 critical review notes that no study has shown structural nerve regeneration.

Benfotiamine is a fat-soluble derivative of thiamine, vitamin B1, and it exists for absorption: ordinary thiamine is water-soluble and its uptake saturates, while benfotiamine reaches higher blood levels from the same milligram figure.

The biochemical argument is attractive. High glucose pushes sugar metabolism down several damaging side routes, and thiamine-dependent enzymes are the ones that divert traffic away from them. On paper, a mechanism aimed at metabolic nerve damage.

The trials thin out. BENDIP randomised people to 300 or 600 mg a day for six weeks and found the clearer result at the higher dose. The earlier BEDIP pilot used 400 mg a day for three weeks. Both are small and short by the standards of the alpha lipoic acid programme, and the 2026 critical review treats the two ingredients very differently for that reason.

The sensible reading: a plausible mechanism, 300 to 600 mg a day in the only trials anyone cites, and a weaker evidence base than the reputation implies.

Acetyl L-carnitine moves fatty acids into mitochondria and supplies acetyl groups for other reactions. The nerve interest came from animal work on fibre regeneration, a stronger claim than anything else in this guide makes.

The human trials are why the dose matters. An analysis of two 52-week randomised trials gave 1,500 or 3,000 mg a day, and the pain benefit appeared only in the 3,000 mg group. A later meta-analysis of neuropathic pain trials pooled the field and found an effect, while the Cochrane review judged the evidence uncertain even at full dose.

One rule falls out of those three. This is a gram-scale ingredient, so a label carrying tens of milligrams of it is carrying a name rather than a dose, and nothing can honestly be said about that amount in either direction.

The clearest link to nerves in the whole category, and the most oversold. A deficiency of vitamin B12 damages nerves, and the clinical literature is unambiguous that correcting it helps. What does not follow is that more B12 helps somebody whose level is normal. The Cochrane review of B vitamins for nerve symptoms found the trial evidence too limited to support that.

Being on this list is a reason for a blood test rather than a guess. A diagnosed deficiency is treated far above anything on a supplement panel.

Three more points belong here, and two of them are about risk.

• Folic acid can hide a B12 deficiency. It corrects the anaemia while nerve damage continues, which is the argument for testing B12 rather than taking more of everything. Expert committees set 1,000 mcg a day as the folic acid upper intake.
• Vitamin B6 is neurotoxic in excess. It causes nerve damage by overdose as well as by shortage, documented since 1983. Ordinary label amounts are nowhere near that range; the risk is stacking several products that each contain it. A 2023 systematic review found no trials of B6 alone for nerve symptoms.
• A daily-requirement amount does what a daily requirement does. It covers a shortfall if you have one, and somebody with normal levels should expect nothing from it.

Low vitamin D turns up more often in people with nerve damage. A meta-analysis of the association studies found the pattern consistently, and it is the reason vitamin D appears on so many nerve labels.

An association points two ways. People with painful nerve symptoms move less and go outside less, which lowers vitamin D on its own, so the shortfall may be a consequence rather than a cause.

The trials that would settle it are thin. A 2025 meta-analysis of supplementation trials for painful neuropathy found four usable studies totalling 320 people, and concluded the evidence was not strong enough to recommend routine use. A sensible daily amount is sensible nutrition rather than a treatment.

Ashwagandha, turmeric and broccoli turn up on nerve labels constantly, and one issue runs through all three: what the research used is not what a label usually contains.

One rule comes out of all three, and it is the most useful thing in this guide. A milligram of powder and a milligram of standardised extract are not the same unit. An extract states a ratio or a percentage, so the active compound can be calculated. A powder states a plant, and the content depends on the crop, the batch and the processing, which is why a comparison against a trial dose has to be made in matching units before it means anything.

Every figure in the second column is a dose a published trial administered, mostly in people with diabetic nerve damage. None of it is a promise about any product.

Hold any bottle against that second column and most of the category answers itself. Where a label lands inside the researched range, the ingredient is at least in the region its evidence came from. An order of magnitude below, and the row is a name on a panel. The checklist guide turns this into seven checks you can run in a minute.

Dietary supplements in the United States may carry structure and function claims: a claim of that kind says what a nutrient is understood to do in the body, may not name a disease, and must carry the federal statement that it has not been evaluated by the Food and Drug Administration.

That is the whole permitted range, and it is narrow by design. Supports nerve health sits inside it. Treats neuropathy, relieves sciatica and reduces nerve pain all sit outside it, because pain relief is a drug claim whoever makes it.

The rule is not a technicality that clever wording gets around. A product that genuinely relieved nerve pain would be a drug and would need trials on the finished formulation. When a sales page promises more than the bottle does, the bottle is the document written under legal constraint.

Four questions separate a citation that supports a sentence from one that decorates it, and none needs a statistics background.

Run those four and most marketing citations collapse into something smaller and more honest, which is usually still worth knowing.